Literature DB >> 10075165

Safety and immunogenicity of hepatitis A vaccine in infants: a candidate for inclusion in the childhood vaccination programme.

M Piazza1, A Safary, A Vegnente, R Soncini, P Pensati, M Sardo, R Orlando, G Tosone, L Picciotto.   

Abstract

Forty-eight infants received a single dose (720 ELISA units = 0.5 ml) of inactivated hepatitis A vaccine at the fifth month of age with booster at the 11th month of age, together with the second and third doses of the vaccines compulsory under Italian law (diphtheria, tetanus, oral polio and hepatitis B). Overall, the seroconversion rate was 100%. The anti-HAV geometric mean titre (GMT) reached 3,021 mIU/ml in infants born to anti-HAV-negative mothers, but only 399 mIU/ml in infants born to anti-HAV-positive mothers. Hepatitis A vaccine was immunogenic, safe and well tolerated without significant side-effects. There seems to be no reason for not including it in childhood vaccination programmes particularly in low endemic HAV areas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10075165     DOI: 10.1016/s0264-410x(98)00237-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  H2 strain attenuated live hepatitis A vaccines:protective efficacy in a hepatitis A outbreak.

Authors:  Yu-Liang Zhao; Zong-Da Meng; Zhi-Yi Xu; Jun-Jie Guo; Shao-Ai Chai; Cheng-Gang Duo; Xuan-Yi Wang; Jin-Feng Yao; Hong-Bin Liu; Shun-Xiang Qi; Hui-Bin Zhu
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

Review 2.  Active immunization in the United States: developments over the past decade.

Authors:  P H Dennehy
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 3.  Aventis Pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data.

Authors:  E Vidor; R Dumas; V Porteret; F Bailleux; K Veitch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-06       Impact factor: 3.267

4.  Persistence of seropositivity among persons vaccinated for hepatitis A during infancy by maternal antibody status: 15-year follow-up.

Authors:  Philip R Spradling; Lisa R Bulkow; Susan E Negus; Chriss Homan; Michael G Bruce; Brian J McMahon
Journal:  Hepatology       Date:  2016-02-01       Impact factor: 17.425

5.  Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020.

Authors:  Noele P Nelson; Mark K Weng; Megan G Hofmeister; Kelly L Moore; Mona Doshani; Saleem Kamili; Alaya Koneru; Penina Haber; Liesl Hagan; José R Romero; Sarah Schillie; Aaron M Harris
Journal:  MMWR Recomm Rep       Date:  2020-07-03

6.  Hepatitis A vaccination.

Authors:  Li Zhang
Journal:  Hum Vaccin Immunother       Date:  2020-07-10       Impact factor: 3.452

Review 7.  Hepatitis A, hepatitis B, and combination hepatitis vaccines for immunoprophylaxis: an update.

Authors:  Raymond S Koff
Journal:  Dig Dis Sci       Date:  2002-06       Impact factor: 3.487

8.  Vaccination against hepatitis A in children: A review of the evidence.

Authors:  Paolo Bonanni; Sara Boccalini; Angela Bechini
Journal:  Ther Clin Risk Manag       Date:  2007-12       Impact factor: 2.423

Review 9.  A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines.

Authors:  David B Huang; Jashin J Wu; Stephen K Tyring
Journal:  J Infect       Date:  2004-10       Impact factor: 6.072

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.